Work

SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.4511

Authors: David I. Quinn, Catherine M. Tangen, Maha Hussain, Primo Lara, Amir Goldkorn, Mark Garzotto, Philip C. Mack, Michael Anthony Carducci, J. P. Monk, Przemyslaw Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Celestia S. Higano, Nicholas J. Vogelzang, Ian Murchie Thompson

Institutions: USC Norris Comprehensive Cancer Center, U-M Rogel Cancer Center, University of California, Davis, Portland VA Medical Center, Johns Hopkins University, The Ohio State University, City Of Hope National Medical Center, City of Hope, The University of Kansas Cancer Center, University of Utah, Huntsman Cancer Institute, Seattle Cancer Care Alliance, University of Washington, Comprehensive Cancer Centers of Nevada, The University of Texas at San Antonio Health Science Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2604052441

Cites:

Cited by: 30

Related to: 10